The DOI matches its Crossref record; 421 of the 421 references it cites were found in a registry or an index.
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season
Open accessAbstract
This report updates the 2020-21 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2020;69[No. RR-8]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. ACIP makes no preferential recommendation for a specific vaccine when more than one licensed, recommended, and age-appropriate vaccine is available. During the 2021-22 influenza season, the following types of vaccines are expected to be available: inactivated influenza vaccines (IIV4s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4).The 2021-22 influenza season is expected to coincide with continued circulation of SARS-CoV-2, the virus that causes COVID-19. Influenza vaccination of persons aged ≥6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient visits, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at https://www.cdc.gov/vaccines/pandemic-guidance/index.html. Recommendations for the use of COVID-19 vaccines are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html, and additional clinical guidance is available at https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.Updates described in this report reflect discussions during public meetings of ACIP that were held on October 28, 2020; February 25, 2021; and June 24, 2021. Primary updates to this report include the following six items. First, all seasonal influenza vaccines available in the United States for the 2021-22 season are expected to be quadrivalent. Second, the composition of 2021-22 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09 and influenza A(H3N2) components. U.S.-licensed influenza vaccines will contain hemagglutinin derived from an influenza A/Victoria/2570/2019 (H1N1)pdm09-like virus (for egg-based vaccines) or an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like virus (for cell culture-based and recombinant vaccines), an influenza A/Cambodia/e0826360/2020 (H3N2)-like virus, an influenza B/Washington/02/2019 (Victoria lineage)-like virus, and an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus. Third, the approved age indication for the cell culture-based inactivated influenza vaccine, Flucelvax Quadrivalent (ccIIV4), has been expanded from ages ≥4 years to ages ≥2 years. Fourth, discussion of administration of influenza vaccines with other vaccines includes considerations for coadministration of influenza vaccines and COVID-19 vaccines. Providers should also consult current ACIP COVID-19 vaccine recommendations and CDC guidance concerning coadministration of these vaccines with influenza vaccines. Vaccines that are given at the same time should be administered in separate anatomic sites. Fifth, guidance concerning timing of influenza vaccination now states that vaccination soon after vaccine becomes available can be considered for pregnant women in the third trimester. As previously recommended, children who need 2 doses (children aged 6 months through 8 years who have never received influenza vaccine or who have not previously received a lifetime total of ≥2 doses) should receive their first dose as soon as possible after vaccine becomes available to allow the second dose (which must be administered ≥4 weeks later) to be received by the end of October. For nonpregnant adults, vaccination in July and August should be avoided unless there is concern that later vaccination might not be possible. Sixth, contraindications and precautions to the use of ccIIV4 and RIV4 have been modified, specifically with regard to persons with a history of severe allergic reaction (e.g., anaphylaxis) to an influenza vaccine. A history of a severe allergic reaction to a previous dose of any egg-based IIV, LAIV, or RIV of any valency is a precaution to use of ccIIV4. A history of a severe allergic reaction to a previous dose of any egg-based IIV, ccIIV, or LAIV of any valency is a precaution to use of RIV4. Use of ccIIV4 and RIV4 in such instances should occur in an inpatient or outpatient medical setting under supervision of a provider who can recognize and manage a severe allergic reaction; providers can also consider consulting with an allergist to help identify the vaccine component responsible for the reaction. For ccIIV4, history of a severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency or any component of ccIIV4 is a contraindication to future use of ccIIV4. For RIV4, history of a se
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–421 of 421
Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine
Roches, A. D., Samaan, K., Graham, F. J., Lacombe‐Barrios, J., Paradis, J., Paradis, L. P., & Serres, G. D. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.08.008 · Cited by 32
Hartvickson, R., Cruz, M., Ervin, J. E., Brandon, D. M., Forleo‐Neto, E., Dagnew, A. F., Chandra, R., LINDERT, K. A., & Mateen, A. A. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.11.004 · Cited by 32
McNeil, S., Noya, F., Dionne, M., Predy, G., Meekison, W., Ojah, C., Ferro, S., Mills, E. L., Langley, J. M., & Halperin, S. A. (2007) · Vaccine · doi:10.1016/j.vaccine.2006.12.047 · Cited by 31
Huang, W., Tang, F.-W., Yang, S.-E., Chih, Y.-C., & Chuang, J.-H. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.09.054 · Cited by 31
Incompletely matched influenza vaccine still provides protection in frail elderly
Dean, A. S., Moffatt, C. R. M., Rosewell, A. E., Dwyer, D. E., Lindley, R. I., Booy, R., & MacIntyre, C. R. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.024 · Cited by 31
Ali, T., Scott, N., Kallas, W. M., Halliwell, M. E., Savino, C., Rosenberg, E. S., Ferraro, M. J., & Hohmann, E. L. (2004) · Clinical Infectious Diseases · doi:10.1086/382887 · Cited by 31
Coleman, L. A., Waring, S. C., Irving, S. A., Vandermause, M., Shay, D. K., & Belongia, E. A. (2012) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2012.00377.x · Cited by 29
Hennessy, T. W., Bruden, D. J. T., Castrodale, L. J., Komatsu, K. K., Erhart, L. M., Thompson, D., Bradley, K. D., O’Leary, D. R., McLaughlin, J. B., Landen, M., et al. (2015) · Epidemiology and Infection · doi:10.1017/s0950268815001211 · Cited by 29
Moro, P. L., Winiecki, S. K., Lewis, P., Shimabukuro, T. T., & Cano, M. V. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.084 · Cited by 26
Prospective Cohort Study of the Safety of an Influenza A(H1N1) Vaccine in Pregnant Chinese Women
Ma, F., Zhang, L., Jiang, R., Zhang, J., Wang, H., Gao, X., Li, X., & Liu, Y. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00375-14 · Cited by 24
Haber, P., Moro, P. L., Cano, M. V., Vellozzi, C. J., Lewis, P., Woo, E. J., & Broder, K. R. (2014) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piu034 · Cited by 24
Self-citationTalbot, H. K., Nian, H., Chen, Q., Zhu, Y., Edwards, K. M., & Griffin, M. R. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.037 · Cited by 24
Febrile Seizures After 2010–2011 Trivalent Inactivated Influenza Vaccine
Kawai, A. T., Martin, D., Kulldorff, M., Li, L., Cole, D. V., McMahill‐Walraven, C. N., Selvam, N., Selvan, M. S., & Lee, G. M. (2015) · PEDIATRICS · doi:10.1542/peds.2015-0635 · Cited by 21
Wongsurakiat, P., Maranetra, K. N., GULPRASUTDILOG, P., AKSORNINT, M., SRILUM, W., RUENGJAM, C., & SATED, W. (2004) · Respirology · doi:10.1111/j.1440-1843.2004.00616.x · Cited by 21
Sheldon, E. A., Jeanfreau, R. J., Sliman, J. A., Charenkavanich, S., Rousculp, M. D., Dubovsky, F., & Mallory, R. M. (2012) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12027 · Cited by 16
Gefenaitė, G., Rahamat-Langendoen, J. C., Ambrozaitis, A., Mickienė, A., Jančorienė, L., Kuliešė, M., Vėlyvytė, D., Niesters, H. G. M., Stolk, R. P., Žagminas, K., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.12.021 · Cited by 16
Moro, P. L., Arana, J. S. V., Cano, M. V., Menschik, D., Yue, X., Lewis, P., Haber, P., Martin, D., & Broder, K. R. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis256 · Cited by 16
Self-citationSafety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children
Curtis, D. J., Ning, M. F., Armon, C., Li, S., & Weinberg, A. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.082 · Cited by 15
Efficacy and safety of influenza vaccination in children with asthma
Patria, M. F., Tenconi, R., & Esposito, S. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.2 · Cited by 10
Suzuki, M., Torii, Y., Kawada, J., Kimura, H., Kamei, H., Onishi, Y., Kaneko, K., Ando, H., Kiuchi, T., & Ito, Y. (2013) · Microbiology and Immunology · doi:10.1111/1348-0421.12086 · Cited by 8
King, J. C., Lichenstein, R., & Magder, L. S. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.054 · Cited by 8
Cited by
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
Jain, S., Self, W. H., Wunderink, R. G., Fakhran, S., Balk, R., Bramley, A. M., Reed, C., Grijalva, C. G., Anderson, E. J., Courtney, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500245 · Cited by 2,323
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001029 · Cited by 1,611
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.053 · Cited by 824
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Metadata
- Authors
- Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B.
- Venue
- MMWR. Recommendations and Reports
- Published
- 2018-08-24
- Volume
- 67
- Issue
- 03
- Pages
- 1-20
- ISSN
- 1057-5987 (ISSN-L)
- 1545-8601
- OpenAlex
- W2785073138
- Cited by
- 1,632
- References
- 421
- FWCI
- 145.91
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.